Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 10, 2022 16:05 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements

TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; anticipated NDA submission in the second half of this year Cash runway expected into at least 2026 ...
May 06, 2022 09:00 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus to Present at Bank of America 2022 Healthcare Conference

IRVINE, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
May 05, 2022 08:30 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting

IRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
May 03, 2022 06:58 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common Stock

IRVINE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new...
May 02, 2022 07:01 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock

IRVINE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new...
May 02, 2022 07:00 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year

TP-03 met the primary and all secondary endpoints, effectively resolved Demodex blepharitis and was well-tolerated with no serious treatment-related adverse events 56% of patients on TP-03 achieved...
April 29, 2022 21:23 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis

IRVINE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
April 26, 2022 08:30 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting

IRVINE, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
March 14, 2022 16:05 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business Achievements

Expecting Saturn-2 Phase 3 topline data in April 2022, the second pivotal of TP-03 for the treatment of Demodex blepharitis, and NDA submission this year Advancing pipeline this year with planned...
March 09, 2022 17:00 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus to Present at Upcoming Investor Conferences

IRVINE, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...